Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR1D | P28221 | 2/20 | 0.36 |
| ▸ | HTR1B | P28222 | 2/20 | 0.36 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.35 |
| ▸ | KDM5A | P29375 | 1/20 | 0.33 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.33 |
| ▸ | GGPS1 | O95749 | 1/20 | 0.31 |
| ▸ | FDPS | P14324 | 1/20 | 0.31 |
| ▸ | AGTR1 | P30556 | 1/20 | 0.31 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.31 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.31 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12788323 | 0.86 | HTR1D (0.36) | HTR1DHTR1B | |
| SCHEMBL15510946 | 0.84 | KDM5A (0.31) | KDM5AKDM4C | |
| SCHEMBL13801838 | 0.80 | FDPS (0.35) | FDPSCHRM2 | |
| SCHEMBL23396341 | 0.78 | KDM5A (0.33) | KDM5AKDM4CCHRM2 | |
| SCHEMBL26004844 | 0.77 | KDM4E (0.32) | HTR1DHTR1BFDPSOPRM1CHRM2 | |
| SCHEMBL12380889 | 0.77 | CHRM2 (0.33) | KDM5AKDM4CCHRM2 | |
| SCHEMBL1106440 | 0.77 | ALDH1A1 (0.43) | HTR1B | |
| SCHEMBL26786815 | 0.76 | GNAI3 (0.40) | SIGMAR1 | |
| SCHEMBL21335502 | 0.76 | CA12 (0.33) | — | |
| SCHEMBL20314557 | 0.75 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230365563-A1 | QUINAZOLINE COMPOUND AND APPLICATION THEREOF | SHANGHAI PHARMACEUTICALS HOLDING CO., LTD. (CN) | 2023-11-16 | — | — | US | disclosed |
| US-20230365563-A1 | QUINAZOLINE COMPOUND AND APPLICATION THEREOF | SHANGHAI PHARMACEUTICALS HOLDING CO., LTD. (CN) | 2023-11-16 | — | — | US | disclosed |
| WO-2018064557-A1 | SUBSTITUTED FUSED BI- OR TRI- HETEROCYCLIC COMPOUNDS AS EHMT2 INHIBITORS | Epizyme, Inc. (US) | 2018-04-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230365563-A1 | QUINAZOLINE COMPOUND AND APPLICATION THEREOF | KRAS, NRAS, BRAF | HTR1D 3669/4885HTR1B 4423/4885SIGMAR1 2385/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.